secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-09-18T20:30:44+00:00
Accession:  0001104659-26-108952
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics sets LYTENAVA US wholesale acquisition cost at $485/vial
-----------------------------------------------------------------------------

- On Sep 16, 2026, Outlook Therapeutics established LYTENAVA WAC at $485 per vial in the US.
- Pricing applies to LYTENAVA, the company's ophthalmic product; no patient volumes or revenue disclosed.
- WAC is the base wholesale list price; may affect reimbursement and distribution economics.
- No guidance, clinical data, or launch-date details included in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/0001104659-26-108952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/tm2625694d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-108952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer